
Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment
Hamano, Kumiko, Nishiyama, Hiroshi, Matsui, Akiko, Sato, Manaka, Takeuchi, MasakazuVolume:
64
Année:
2017
Langue:
english
Journal:
Endocrine Journal
DOI:
10.1507/endocrj.EJ16-0428
Fichier:
PDF, 747 KB
english, 2017